Status:

UNKNOWN

Telemonitoring Among Patients With Multiple Myeloma

Lead Sponsor:

Isala

Conditions:

Multiple Myeloma

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

A two-arm open-label parallel-group randomized controlled trial will be conducted to compare the telemonitoring (MM e-coach) with standard MM care. This study aimed to recruit 150 patients with recent...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • In order to be eligible to participate in this study, a participant (patient) must meet all of the -following criteria:
  • signed informed consent
  • \>18 years
  • recently diagnosed MM patients with first-line or second-line treatment
  • able to complete patient-reported outcome measures and experiences
  • have minimal digital skills to check if they are able to interact with an e-coach
  • can read and understand Dutch.
  • Participants who meet any of the following criteria will be excluded from participation in this study
  • psychiatric illness requiring secondary-care intervention
  • too ill to engage with the intervention in the opinion of the clinical care team
  • no perspective of \>12 months survival.

Exclusion

    Key Trial Info

    Start Date :

    March 1 2021

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    July 1 2024

    Estimated Enrollment :

    150 Patients enrolled

    Trial Details

    Trial ID

    NCT05964270

    Start Date

    March 1 2021

    End Date

    July 1 2024

    Last Update

    July 27 2023

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Isala Klinieken

    Zwolle, Overijssel, Netherlands, 8012AB